Evotec Subsidiary Just Biologics Moves JST-018 Orthopoxvirus Antibodies Into First-In-Human Phase 1 Study For Biodefense
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures
Evotec's team started testing new medicine designed to fight orthopoxviruses (a type of virus) in people for the very first time. This is an early step that shows the company is making progress on a government-backed project, which suggests investors should watch if the tests go well.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.